By Keith Loria
Veterinary Investigative Desk
Executive Overview
For decades, a diagnosis of feline infectious peritonitis (FIP) was regarded by veterinarians and pet owners alike as an emotional and clinical death sentence. Caused by a mutation of the ubiquitous feline coronavirus, the disease was notoriously difficult to pin down antemortem and uniformly fatal once clinical signs fully manifested.
Today, the landscape of feline medicine has dramatically shifted. The advent of targeted antiviral therapies has transformed FIP from an incurable terminal condition into a highly manageable—and often curable—disease. However, this medical triumph has exposed a glaring paradox in modern veterinary practice: while effective treatments exist, clinicians still lack a single, definitive, and universally dependable diagnostic test capable of confirming or excluding FIP in every patient prior to death.
This diagnostic ambiguity carries high stakes. In an era where a correct diagnosis leads directly to life-saving treatment, uncertainty can result in tragic delays, misallocated financial resources, or the unnecessary administration of potent medications to patients suffering from entirely different pathologies.
Addressing this critical gap, a team of researchers at Colorado State University (CSU) and collaborating institutions has published a groundbreaking diagnostic study evaluating multiplex fluorescent immunocytochemistry (MF-ICC). This innovative assay detects feline coronavirus antigens specifically within macrophages—the hallmark immune cells central to systemic FIP pathogenesis—all without requiring invasive surgical biopsies. While researchers emphasize that MF-ICC is not a standalone "silver bullet," its integration into current diagnostic frameworks represents a major step forward, offering veterinary practitioners a sharper, faster, and more targeted tool in the ongoing battle against feline infectious peritonitis.
Detailed Chronology: The Evolution of FIP Diagnostics
To understand the significance of the MF-ICC assay, one must examine the historical evolution of FIP diagnostics and the persistent hurdles that have frustrated clinicians for generations.
The Diagnostic Gridlock of the Past
Historically, diagnosing FIP relied heavily on piecing together incompatible clues. Feline coronavirus (FCoV) is exceptionally common, particularly in multi-cat environments, catteries, and shelters. The vast majority of cats exposed to the enteric form of the virus never develop FIP. Consequently, traditional testing methods—such as serology to detect antibody responses or standard Reverse Transcription-Polymerase Chain Reaction (RT-PCR) to hunt for viral RNA—frequently yielded ambiguous results. They could confirm exposure to coronavirus, but they struggled to prove that the virus had mutated and was actively driving systemic FIP.
While histopathology paired with immunohistochemistry (IHC) on tissue samples remained the gold-standard definitive diagnosis, obtaining these samples often required risky exploratory surgery or organ biopsies. For a cat already destabilized by systemic illness, invasive procedures were frequently contraindicated.
Developing the MF-ICC Approach
Recognizing the limitations of existing modalities, lead author Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, associate professor of clinical pathology at Colorado State University, and her research collaborators set out to refine how veterinary pathologists look for the virus.
Instead of searching broadly for viral RNA or general antibodies, the research team focused on finding the virus inside its cellular vehicle of choice: the macrophage. The resulting assay, multiplex fluorescent immunocytochemistry (MF-ICC), uses fluorescent antibodies to simultaneously target two distinct markers:
- Feline coronavirus antigens (identifying the presence of the virus).
- Vimentin (a cellular protein marker that specifically highlights macrophages).
By capturing images under different laser wavelengths and superimposing them, technicians can determine with high precision whether both markers are co-localized within the exact same cell.
"The innovation we added was multiplexing [the viral marker] with another marker for cellular antigen called vimentin," explains Dr. Evans. "That cellular marker allows us to look specifically at macrophages, which are the hallmark cell type of FIP."
By confirming viral presence explicitly inside macrophage-like cells, the assay provides evidence far more consistent with systemic FIP than standard coronavirus testing. Furthermore, because samples can be collected via minimally invasive procedures—such as drawing effusion fluid from the abdomen or performing a simple needle aspirate of affected tissues—the procedure can often be performed without general anesthesia.
Supporting Context & Metrics: Putting the Trial to the Test
To rigorously evaluate the efficacy of MF-ICC, the research team conducted a comprehensive clinical trial encompassing 84 feline patients.
Study Design and Patient Cohorts
The study population was carefully curated to mirror real-world veterinary caseloads:
- 58 cats with confirmed FIP.
- 26 control cats suffering from alternative, non-FIP diseases.
Researchers compared the diagnostic performance of MF-ICC against three established methodologies:
- RT-PCR (detecting viral RNA).
- Serology (measuring antibody titers).
- Serum albumin-to-globulin (A:G) ratio (assessing biochemical changes typical of systemic inflammation).
Final case determinations were established using a rigorous standard, relying on necropsy findings with histopathology and immunohistochemistry, documented clinical responses to antiviral therapy, and/or thorough longitudinal clinical follow-up.
Performance Metrics
When researchers applied a conservative threshold of at least one cell positive for both markers (viral antigen and vimentin), MF-ICC demonstrated compelling statistical performance:
- Sensitivity: 77%
- Specificity: 81%
- Positive Predictive Value (PPV): 92%
- Negative Predictive Value (NPV): 53%
- Overall Accuracy: 78%
For comparison within this specific cohort, the other modalities scored as follows:
- Albumin-to-globulin ratio: 76% accuracy
- Serology: 75% accuracy
- RT-PCR: 69% accuracy
Surprising Revelations
One of the most unexpected findings of the trial, according to Dr. Evans, was the astonishingly low threshold required to achieve high diagnostic accuracy. The presence of just a single dual-positive cell was enough to effectively discriminate between FIP and non-FIP disease cases.
"Literally a single virus-infected cell was enough information to discriminate FIP versus non-FIP disease," Dr. Evans notes. "It was surprising to me that little material was clinically significant."
However, the researchers are quick to contextualize these numbers. The overall accuracy of 78% does not mean MF-ICC is a standalone replacement for other tests. Performance varied depending on the sample type and the clinical phenotype of the disease. For instance, MF-ICC demonstrated higher sensitivity but lower specificity when performed on effusion fluids, whereas positive results in tissue samples from cats with the notoriously difficult non-effusive (dry) form of FIP carried exceptionally strong diagnostic weight.
Crucially, the study revealed that different tests do not always flag the same patients. "MF-ICC picked up some FIP cases that PCR did not, and PCR picked up some FIP cases that MF-ICC did not," Dr. Evans points out. "There is value to ordering both. You’ll have a greater chance of picking up an FIP case by submitting both, and the same sample type can be used for these different assays in a complementary way."
Official Statements & Expert Perspectives
The introduction of effective antiviral therapies has fundamentally altered the clinical urgency surrounding FIP diagnoses. Veterinary experts emphasize that diagnostic delays are no longer merely academic concerns—they can spell the difference between life and death.
The Critical Need for Speed
Benjamin Curtis, DVM, DACVP, a clinical assistant professor at the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core and a co-author of the study, underscores the practical advantages of the assay.
"It’s minimally invasive," Dr. Curtis explains. "Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP."
Highlighting the time-sensitive nature of modern treatment, Dr. Curtis adds: "Having something with a rapid turnaround is going to be life and death for a lot of cats. Being able to get a rapid answer lets owners and veterinarians know whether we need to start moving on treatment or make other decisions."
Guarding Against Misdiagnosis and Poor Stewardship
Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, an assistant professor of small animal internal medicine at the University of Georgia and another study co-author, has witnessed firsthand the consequences of diagnostic ambiguity in clinical practice.
"Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."
— Dr. Petra Černá
"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats," Dr. Černá emphasizes. "No single test is perfect, and the more possibilities we have, the better we can diagnose these cats and treat them appropriately."
For general practitioners juggling complex caseloads, MF-ICC offers a reliable fallback option. It can be utilized when cytology samples have already been collected, when no material was retained for RT-PCR, or when a PCR test returns negative despite clinical signs that strongly point toward FIP.
Future Outlook: Building a Comprehensive Diagnostic System
As the veterinary community digests these findings, researchers are already looking ahead to the next phase of FIP diagnostics and management.
Scaling Laboratory Services
MF-ICC is not currently an in-clinic, point-of-care test. It demands sophisticated laboratory infrastructure, including specialized equipment to concentrate cells onto slides, specialized fluorescent reagents, and the trained eye of a board-certified veterinary pathologist to interpret complex staining patterns.
Colorado State University plans to make the assay commercially available through its Veterinary Diagnostic Laboratory, continuously evaluating its performance as field data accumulates. Dr. Evans envisions integrating MF-ICC into a comprehensive, multi-tiered FIP diagnostic service. Rather than relying on a solitary metric, veterinary clinics will soon be able to submit samples for a bundled panel comprising MF-ICC, RT-PCR, biochemical ratios, and patient-specific metadata.
Furthermore, CSU’s growing FIP biobank and digital repository will support ongoing retrospective evaluations, while parallel projects—such as machine-learning tools designed to analyze routine Complete Blood Count (CBC) and serum biochemistry results—aim to streamline risk assessment even further.
Because the published methodology is entirely non-proprietary, other veterinary diagnostic laboratories equipped with the requisite technology can readily adopt the protocol. Broader laboratory adoption will ultimately reduce sample shipping distances and accelerate turnaround times for practitioners nationwide.
Horizon Challenges: Managing Comorbidities and Long-Term Outcomes
While diagnostic accuracy is improving rapidly, veterinary medicine must now confront new frontiers opened up by the success of FIP treatments. Dr. Černá points out that future research must urgently focus on patients that fail to respond predictably to standard antiviral protocols. This includes critically ill cats suffering from severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, and various coinfections.
"We still lose some cats," Dr. Černá notes. "Learning how to best manage these comorbidities to improve prognosis is crucial."
Additionally, as thousands of treated cats survive and enter their golden years, clinicians are observing novel long-term health trends. Anecdotal and reported cases indicate that some recovered patients subsequently develop gastrointestinal complications or large-cell lymphoma—questions of post-treatment survivorship that were entirely academic when FIP was universally fatal.
The Ultimate Goal: A Unified Diagnostic Puzzle
Ultimately, the emergence of MF-ICC reinforces a fundamental truth about modern veterinary medicine: complex diseases demand multifaceted solutions. While the search for a single, instantaneous "silver bullet" diagnostic test continues, innovations like multiplex fluorescent immunocytochemistry successfully bridge the gap between invasive surgical biopsies and ambiguous blood titers.
"There’s no perfect test for FIP," Dr. Evans concludes. "One piece is PCR, one is MF-ICC, and this new test is one part of putting together that puzzle." For practitioners on the frontline of feline care, adding this piece brings them one step closer to delivering definitive answers and life-saving care when every hour counts.
About the Author
A graduate of the University of Miami, Keith Loria is a Washington, D.C.-based, award-winning journalist who has been writing for major publications for close to 20 years on topics as diverse as veterinary medicine, travel, and entertainment. Loria started his career with the Associated Press and has held senior editorial positions at publications focused on healthcare, sports, and technology.
